Replagal agalsidase alfa: Marketed in Europe; under FDA review

TKTX said data from 25 patients in a 12-month open-label extension of its 6-month pivotal Phase II trial showed that 12 Fabry disease patients crossing over to Replagal from placebo had significant im...